UBS AM
ITOS

UBS AM’s iTeos Therapeutics ITOS Stock Holding History

UBS AM’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,154
Closed -$12.9K – 2671
2025
Q1 		$12.9K Buy
+2,154
New +$15.8K ﹤0.01% 2628
2024
Q4 		– Sell
-56,507
Closed -$577K – 2711
2024
Q3 		$577K Sell
56,507
-2,333
-4% -$35.6K ﹤0.01% 2609
2024
Q2 		$873K Buy
58,840
+15,585
+36% +$223K ﹤0.01% 2446
2024
Q1 		$590K Hold
43,255
– – ﹤0.01% 2234
2023
Q4 		$474K Hold
43,255
– – ﹤0.01% 2337
2023
Q3 		$474K Buy
43,255
+18,094
+72% +$231K ﹤0.01% 2320
2023
Q2 		$342K Hold
25,161
– – ﹤0.01% 2435
2023
Q1 		$342K Buy
25,161
+4,024
+19% +$72.1K ﹤0.01% 2435
2022
Q4 		$413K Buy
+21,137
New +$413K ﹤0.01% 2248
2022
Q2 		– Sell
-6,700
Closed -$216K – 2729
2022
Q1 		$216K Buy
+6,700
New +$243K ﹤0.01% 2663

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS AM's ITOS Position: Q2 2025 in Review

UBS AM sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 2,154 shares — an estimated $12.9K sold.

UBS AM first reported a position in ITOS in Q1 2022 and held it in 10 quarters. The position peaked at $873K in Q2 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • UBS AM reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • UBS AM sold 2,154 iTeos Therapeutics shares in Q2 2025, an estimated $12.9K.
  • UBS AM first reported a position in iTeos Therapeutics in Q1 2022 and held it in 10 quarters.
  • UBS AM's iTeos Therapeutics position peaked at $873K in Q2 2024.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on UBS AM's 13F filing for Q2 2025, filed 14 Aug 2025.